Evidence map›Paper›PMID 39445100›Full record

ArticlePatient preference and adherence2024

Patient, Care Partner, and Physician Voices in Treatment Decision-Making for Multiple Myeloma.

Lisa Dwyer Orr, Dee Lin, Bingcao Wu, Thomas W LeBlanc, Beth Faiman, Jenny Ahlstrom, Margaret Yung, Kathleen L Deering, Victoria Kulbokas, Joshua L Feldman and 2 more

Abstract read
In one paragraph

Article in Patient preference and adherence, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lisa Dwyer OrrJanssen Scientific Affairs LLC, Titusville, NJ, USA.
Dee LinJanssen Scientific Affairs LLC, Titusville, NJ, USA.
Bingcao WuJanssen Scientific Affairs LLC, Titusville, NJ, USA.ORCID 0000-0002-7027-8062
Thomas W LeBlancDuke Cancer Institute, Duke University School of Medicine, Durham, NC, USA.
Beth FaimanCleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.
Jenny AhlstromHealthTree Foundation, Draper, UT, USA.
Margaret YungEPI-Q Inc, Chicago, IL, USA.ORCID 0009-0001-2967-6851
Kathleen L DeeringEPI-Q Inc, Chicago, IL, USA.
Victoria KulbokasEPI-Q Inc, Chicago, IL, USA.
Joshua L FeldmanInspire Insights, Arlington, VA, USA.
Erika KlineInspire Insights, Arlington, VA, USA.
Noa BiranHackensack Meridian Health, John Theurer Cancer Center, Hackensack, NJ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Treatment decision-making for multiple myeloma (MM) is complex. Individuals involved in decision-making may value treatment attributes differently based on their role as a patient, care partner, or physician. This study describes those attributes, and what is most important by role. Methods: We conducted a cross-sectional online survey with consenting adult patients with MM, MM care partners, and physicians treating MM. Respondents were recruited from US panels (Inspire and M3 Global Research) between September and December 2022. Survey items were informed by a targeted literature review, qualitative interviews, and a steering committee comprising clinical experts, a patient advocate, patient, and care partner. Descriptive statistics were generated and reported in aggregate. Results: Email invitations were sent to 8071 Inspire members interested in or posting about MM. Of these, 4427 viewed the invitation, 941 responded, and 156 patients and care partners completed the survey (17% of respondents). For physicians, 5588 were invited via Email by M3 Global Research, with 761 viewing the invitation, 214 accessing the survey link, and 137 completing the survey (64% of respondents). Duration of response, side effects, and patients' quality-of-life (QoL) were the top three treatment attributes selected across the three cohorts; alignment of these attributes was consistent among patients regardless of disease severity. Separately, patients rated QoL and the amount of caregiving needed during/after treatment as the most important factors for future treatment decisions. If more effective MM treatments were offered, care partners were more willing to assume greater family burden (77%) compared to patients (49%), and patients were more accepting of potential serious side effects (50%) than were care partners (34%). Conclusion: Patients with MM, care partners, and physicians consider and value various treatment decision-making factors. Recognizing and addressing these differences is critical to meeting patients' preferences, needs, and optimizing patient outcomes.

Indexed as

cross-sectional surveyDecision-makingmultiple myelomatreatment choice

Identifiers

PMID39445100
PMCPMC11498144

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.